Our Mission
"Curing Cancer Through Ferroptosis"
Through decades of research, we have elucidated the fundamental Mechanisms of Action that can induce cancer-specific cell death through ferroptosis. To this end we have endeavored to develop novel small-molecule therapeutics that use ferroptosis as an effective and safe treatment.
By manipulating such fundamental cellular processes our pipeline can extend its target indications to cover a wide range of neoplasms. We at FerroptoCure believe our patented solutions extend far beyond cancer - indeed there is promising data implicating a wide range of treatment opportunities - including neurodegenerative disorders including Alzheimer's & Parkinson's Disease. It is through our efforts that we aim to reach, and treat, the greatest number of patients possible.
Our Members
Yuji Otsuki
M.D.,Ph.D. Chief Executive Officer
Graduated from the Faculty of Medicine, Hokkaido University, and completed his doctorate in medicine at Keio University. He is currently engaged in research and development as the leader of our company's anticancer drug development. He also has experience in managing a clinic.
Currently the project leader at Keio University and Fujita Health University.
Hideyuki Saya
M.D.,Ph.D. Director
Graduated from Kobe University School of Medicine, and completed his doctoral studies (Medicine) at Kobe University. After post-doctoral work at UC San Francisco, he moved to M.D. Anderson. As a professor at Keio University, he has led clinical and translational research.
Currently Director of the Medical Oncology Research Center at Fujita Health University
Osamu Nagano
DDS., Ph.D. Director
Graduated from Hiroshima University School of Dentistry and completed his doctorate in medicine at Kumamoto University. Led the basic research that formed the basis of our anti-cancer drug development.
Currently a professor at Fujita Health University
Toru Natsume
Ph.D. Director
Graduated from the Graduate School of Agriculture at the University of Tokyo and completed his doctoral studies at Kyoto University (Medicine). Engaged in drug discovery research as the Director of the Research Center at AIST. Has experience in multiple ventures.
Currently Chief Researcher at AIST / CSO at RBI
Nobuhiro Nishiyama
Ph.D. Director
Completed his doctoral studies in engineering at the University of Tokyo. Leads drug development using drug delivery systems.
Currently Professor at Tokyo University of Science
About Us
| Company | FerroptoCure Inc. |
| Location | 4F Duplex B's, 1-3-11 Fujimi, Chiyoda, Tokyo, Japan |
| Establishment | 30/05/22 |
| Capital | 60,000,000yen |
| Business | Development of Ferroptosis-Inducing Anti-Cancer Therapeutics |
| CEO | Yuji Otsuki |